{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreieydq3jyllrpxrugf3imfzwgjifw3sv4iab4uqj2zal265d6wdqfm",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mjw2jfetx5d2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreihoro3nhi6n6swgxv5k4oybk7k7n5llarmztypsjngpivelpnvwl4"
    },
    "mimeType": "image/jpeg",
    "size": 25117
  },
  "path": "/2026/04/19/daraxonrasib-pancreatic-cancer-kras-revolution-medicines-patient-story/?utm_campaign=rss",
  "publishedAt": "2026-04-19T08:30:00.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "Health",
    "Pharma",
    "Special Report",
    "AACR",
    "biotech",
    "Cancer",
    "drug development",
    "pharma",
    "research",
    "STAT+"
  ],
  "textContent": "Daraxonrasib, a pancreatic cancer drug from Revolution Medicines, is showing unprecedented success. For patients like Leanna Stokes, survival time doubled.",
  "title": "STAT+: The race to catch KRAS, pancreatic cancer’s ‘greasy ball,’ and create the most promising drug in decades",
  "updatedAt": "2026-04-19T22:15:46.000Z"
}